-

Carlsmed Announces FDA Clearance for aprevo® Cervical Breakthrough Fusion Device

CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, Inc. (“Carlsmed” or the “Company”) a MedTech company pioneering AI-enabled personalized spine surgery, today announced FDA 510(k) clearance for the aprevo® Cervical ACDF Interbody System. This milestone underscores Carlsmed’s commitment to advancing patient-specific spine surgery solutions that enhance outcomes and surgical precision.

The FDA previously granted Breakthrough Device designation for Carlsmed’s aprevo® technology for the treatment of patients with cervical spine disease, recognizing aprevo’s potential to address unmet clinical needs and deliver superior patient care. The Company’s current portfolio of aprevo® interbody fusion devices for the treatment of lumbar spine disease is commercially available in the U.S.

“This 510(k) clearance is a major step forward in our mission to make personalized spine surgery the standard of care,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “More than 350,000 cervical fusion surgeries are performed annually in the U.S. The aprevo® Cervical ACDF Interbody System will set a new benchmark for improving outcomes for these patients.”

Designed to match the unique anatomical and procedural needs of each patient, personalized interbody devices have demonstrated significant improvements in patient outcomes compared to traditional fusion methods, as highlighted in recent clinical publications. The aprevo® devices are designed using Carlsmed’s proprietary technology platform that leverages AI-driven surgical planning software and digital production to create the personalized spine fusion devices that can be delivered in under two weeks.

“Personalized interbody devices like aprevo® provide surgeons with tools designed to address each patient’s unique anatomy,” said Joseph Osorio, MD, PhD, and neurosurgeon at UC San Diego. “Having this technology available for cervical fusions marks a significant advancement in spinal surgery, with the potential to transform procedures by replacing the limitations of one-size-fits-all implants with level-specific customization, offering enhanced surface coverage and precise alignment, both of which are critical for improving patient outcomes.”

Carlsmed plans to commercially launch the aprevo® Cervical ACDF Interbody System in the U.S. in 2025, expanding its innovative product portfolio to further solidify its leadership in the personalized spine surgery market.

About Carlsmed

Carlsmed is a high-growth medical technology leader and pioneer in the personalized spine surgery market. Carlsmed’s mission is to revolutionize the standard of care in spine surgery by providing cutting-edge solutions tailored to the unique needs of each patient. The Company’s innovative aprevo® Technology Platform combines proprietary AI-driven software with patient-specific fusion devices to personalize surgical procedures, improve patient outcomes, and reduce complications. For more information, visit carlsmed.com or contact info@carlsmed.com.

Contacts

For media and investor inquiries, please contact Jodi Allen at jodi@carlsmed.com.

Industry:

Carlsmed, Inc.

Release Versions
English
Hashtags
#Carlsmed
#MedTech
#MedicalDevice
#PersonalizedSurgery
#Spine
#SpineSurgery
#SurgicalDevice
#aprevo

Contacts

For media and investor inquiries, please contact Jodi Allen at jodi@carlsmed.com.

Social Media Profiles
LinkedIn
Twitter
More News From Carlsmed, Inc.

Carlsmed Launches Cutting-Edge Digital Production Line, Revolutionizing Spine Surgery

CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, a commercial-stage medical technology company and pioneer of the personalized spine surgery market, today announced the successful launch of its state-of-the-art digital production line. This innovative technology will enable the company to deliver its aprevo® personalized spinal fusion implants to hospitals in less than ten days. “This advancement is more than just a technical achievement,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “The re...

Carlsmed Adds Industry Veteran, Kevin O’Boyle, to Board of Directors

CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, the leader in personalized spine surgery, announced that Kevin O’Boyle has joined its Board of Directors and will serve as the Chair of the Audit Committee. Mr. O’Boyle previously served as a director of seven publicly traded companies, including Wright Medical Group (WMGI), GenMark Diagnostics (GNMK) and Zeltiq (ZLTQ). In addition to Carlsmed, he currently serves on the board of Nevro (NVRO). Mr. O’Boyle has over 20 years of executive management exp...

Carlsmed Announces Favorable Medicare Reimbursement Decision for Spinal Fusions with Custom-Made Anatomically Designed Devices

CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, the leader in personalized spine surgery, announced today that in the Hospital Inpatient Prospective Payment System Final Rule for fiscal year 2025, the Centers for Medicare & Medicaid Services (CMS) assigned spinal fusion cases with aprevo® custom-made anatomically designed interbody fusion devices to the highest level of the new spinal fusion Medicare Severity-Diagnosis Related Groups (MS-DRGs) it created. The new assignments and payment rates...
Back to Newsroom